PCSK9 Protein (AA 31-692) (His tag)

Produktnummer ABIN7275415

Produktdetails

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Protein-Typ: Recombinant

Proteineigenschaft: AA 31-692

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses PCSK9 Protein ist gelabelt mit His tag.

Verwendungszweck: Human PCSK9 Protein

Sequenz: Gln31-Gln692

Produktmerkmale: Recombinant Human PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln31-Gln692.

Reinheit: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 1EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human PCSK9, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-PCSK9 antibody, hFc Tag with the EC50 of 0.16μg/ml determined by ELISA. The affinity constant of 0.35 nM as determined in SPR assay (Biacore T200). See testing image for detail.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Supplied as 0.22μm filtered solution in 20 mM PB, 300 mM NaCl, 10 % Glycerol ( pH 7.4).

Lagerung: -80 °C

Informationen zur Lagerung: Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Andere Bezeichnung: PCSK9 (PCSK9 Produkte)

Synonyme: FH3 Protein, HCHOLA3 Protein, LDLCQ1 Protein, NARC-1 Protein, NARC1 Protein, PC9 Protein, AI415265 Protein, AI747682 Protein, Narc1 Protein, proprotein convertase subtilisin/kexin type 9 Protein, proprotein convertase subtilisin/kexin type 9 L homeolog Protein, PCSK9 Protein, pcsk9.L Protein, pcsk9 Protein, Pcsk9 Protein

Hintergrund: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

Molekulargewicht: Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Tris-Bis PAGE result.